Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 190

Related Articles by Review for PubMed (Select 22999165)

1.

Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.

Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, Rutks I, Wilt TJ.

Am J Kidney Dis. 2012 Nov;60(5):747-69. doi: 10.1053/j.ajkd.2012.07.017. Epub 2012 Sep 19. Review.

PMID:
22999165
2.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

3.

Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline.

Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ.

Ann Intern Med. 2012 Apr 17;156(8):570-81. doi: 10.7326/0003-4819-156-8-201204170-00004. Review.

PMID:
22508734
4.

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM.

Ann Intern Med. 2012 Aug 21;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005. Review.

PMID:
22910936
5.

KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.

Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PW, Fried L.

Am J Kidney Dis. 2015 Mar;65(3):354-66. doi: 10.1053/j.ajkd.2014.10.005. Epub 2014 Nov 18. Review.

PMID:
25465166
6.

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C.

BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. Review.

7.

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.

Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Manfreda VM, Gentile G, Strippoli GF.

Nephrol Dial Transplant. 2011 Sep;26(9):2827-47. doi: 10.1093/ndt/gfq792. Epub 2011 Mar 3. Review.

8.

Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia.

Shogbon AO, Levy SB.

Am J Health Syst Pharm. 2010 May 15;67(10):798-805. doi: 10.2146/ajhp090211. Review.

PMID:
20479101
9.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
10.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
11.

Intensive insulin therapy in hospitalized patients: a systematic review.

Kansagara D, Fu R, Freeman M, Wolf F, Helfand M.

Ann Intern Med. 2011 Feb 15;154(4):268-82. doi: 10.7326/0003-4819-154-4-201102150-00008. Review.

PMID:
21320942
12.

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.

Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR.

Arch Intern Med. 2012 May 28;172(10):761-9. doi: 10.1001/archinternmed.2011.2230. Review. Erratum in: Arch Intern Med. 2012 Jul 23;172(14):1095.

13.

Treatment of microalbuminuria in patients with type 2 diabetes mellitus.

Jerums G, MacIsaac RJ.

Treat Endocrinol. 2002;1(3):163-73. Review.

PMID:
15799209
14.

Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment [Internet].

Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jan.

15.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
16.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

17.

Systematic review: glucose control and cardiovascular disease in type 2 diabetes.

Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J.

Ann Intern Med. 2009 Sep 15;151(6):394-403. Epub 2009 Jul 20. Review.

PMID:
19620144
18.
19.

Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V.

J Am Coll Cardiol. 2012 Nov 13;60(20):2061-71. doi: 10.1016/j.jacc.2012.07.049. Epub 2012 Oct 17. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk